Market Overview

Edison Investment Research Comments on Halozyme Therapeutics on Multiple Value Drivers

Share:
Related HALO
Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 2
Benzinga's Volume Movers
Next Week In Biotech: Pacira PDUFA, Geron And Dendreon Report (Seeking Alpha)

In a report published Friday, Edison Investment Research analyst Jason Zhang commented on recent developments related to Halozyme Therapeutics (NASDAQ: HALO).

In the report, Edison Investment Research noted, “With a positive CHMP opinion received for Herceptin SC, Halozyme is moved a step closer to being able to reap the full commercial potential of its rHuPH20 platform, which is being used to develop subcutaneous (sc) formulations of leading IV drugs for Roche and other partners. This opportunity currently drives Halozyme's valuation, but we contend that the market is ignoring certain key pipeline assets, notably PEGPH20, which is in a Phase II study in pancreatic cancer.”

Halozyme Therapeutics closed on Wednesday at $7.69.

Latest Ratings for HALO

DateFirmActionFromTo
Jan 2015JP MorganMaintainsOverweight
Dec 2014MLV & Co. Initiates Coverage onBuy
Dec 2014JP MorganMaintainsOverweight

View More Analyst Ratings for HALO
View the Latest Analyst Ratings

Posted-In: Edison Investment Research Jason ZhangAnalyst Color Analyst Ratings

 

Related Articles (HALO)

Around the Web, We're Loving...

Get Benzinga's Newsletters